Showing results (331-340 of 758) with videos related to

Sort By:
Pageof 76
The Lancet. Gastroenterology & Hepatology|January 19, 2026
ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trialMan-Fung Yuen, Kosh Agarwal, Alina Jucov, et al.
The Lancet. Gastroenterology & Hepatology|November 21, 2025
Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trialJess L Kaplan, Athos Bousvaros, Dan Turner, et al.
The Lancet. Gastroenterology & Hepatology|November 16, 2025
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trialVipul Jairath, Silvio Danese, Geert R D'Haens, et al.
The Lancet. Gastroenterology & Hepatology|January 9, 2026
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort studyEva Visser, Maud A Reijntjes, Lianne Heuthorst, et al.
The Lancet. Gastroenterology & Hepatology|October 30, 2025
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort studyGeert R D'Haens, Mark Löwenberg, Filip Baert, et al.
The Lancet. Gastroenterology & Hepatology|July 4, 2025
Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association studyVincent W Joustra, Andrew Y F Li Yim, Peter Henneman, et al.
The Lancet. Gastroenterology & Hepatology|September 15, 2025
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysisCiro Celsa, Grazia Pennisi, Adele Tulone, et al.
The Lancet. Gastroenterology & Hepatology|May 17, 2025
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trialEvan S Dellon, Margaret H Collins, Albert J Bredenoord, et al.
The Lancet. Gastroenterology & Hepatology|May 23, 2025
A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profilesLindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, et al.
The Lancet. Gastroenterology & Hepatology|May 23, 2025
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profilesLindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, et al.
Pageof 76